期刊文献+

DP与NP方案治疗复发转移乳腺癌临床观察 被引量:1

The clinical study of docetaxel plus cisplatin versus vinorelbine plus cisplatin in the therapeutics of recurrent and/or metastatic breast cancers
下载PDF
导出
摘要 目的观察多西紫杉醇联合顺铂(DP方案)与诺维本联合顺铂(NP方案)治疗复发、转移乳腺癌的疗效及不良反应。方法58例乳腺癌患者随机分为2组进行治疗。DP方案28例:多西紫杉醇75 mg/m2,静脉输注,第1天;顺铂25 mg/m2,静脉输注,第2、3、4天。NP方案30例:诺维本25 mg/m2,静脉输注,第1、8天;顺铂用法同DP组。每21天为1个治疗周期。结果DP方案总有效率(57.1%)与NP方案总有效率(43.3%)差异无统计学意义(P>0.05);不良反应以胃肠道反应、骨髓抑制为主,经治疗后可耐受。结论DP方案与NP方案对复发、转移乳腺癌均有较好疗效,蒽环类药物治疗失败的患者可选用。 Objective To evaluate the efficacy and adverse reactions of docetaxel plus cisplatin(DP) and vinorelbine plus cisplatin(NP) combinations in the therapeutics of the recurrence and metastasis of breast cancer.Methods 58 patients with breast cancer were divided into two groups at random.28 patients in group DP received intravenous dripping of docetaxel 75 mg/m^2 on the 1st day and cisplatin 25 mg/m^2 on the 2nd,3rd and 4th days.30 patients in group NP received intravenous dripping of vinorelbine 25 mg/m^2 on the 1st and 8th days and cisplatin 25 mg/m^2 on the 2nd,3rd and the 4th days.Both regimens were repeated every 3 weeks.Results The overall response rate for group DP was 57.1%(16/28),and in group NP,the overall response rate was 43.3%(13/30),there was no significant difference(P〉0.05).The adverse reactions,which were mainly nausea /vomiting and myelosuppression,were tolerable after treatment.Conclusion Both DP and NP combined chemotherapy produced similar effects and are well tolerated in the patients with recurrent and/or metastatic breast cancer,and can serve as an alternative for failures with anthracyclines.
出处 《徐州医学院学报》 CAS 2008年第12期814-816,共3页 Acta Academiae Medicinae Xuzhou
关键词 乳腺肿瘤 多西紫杉醇 顺铂 诺维本 化学疗法 转移 复发 breast neoplasms docetaxel cisplatin vinorelbine chemotherapy metastasis recurrence
  • 相关文献

参考文献3

  • 1Heinemann V. Role of gemcitabine in the treatment of advanced and metastatic breast cancer [ J ]. Oncology, 2003,64 ( 3 ) : 191 - 206.
  • 2Okouneva T, Hill BT, Wilson L, et al. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics [ J ]. Mol Cancer Ther,2003,2 ( 5 ) :427 - 436.
  • 3徐兵河,李维廉,邸立军.诺维本联合顺铂治疗晚期乳腺癌的多中心临床研究[J].中国肿瘤临床,2004,31(23):1340-1342. 被引量:27

二级参考文献4

  • 1Ray-Coquard I, Biron P, Bachelot T, et al. Vinorelbine and cisplatin (CMC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline-and/or paclitaxel- contaning regimens[J]. Cancer, 1998, 82(1):134~140
  • 2Shamseddine AI, Taher A, Dabaja B, et al. Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer[J]. Am J Clin Oncol, 1999, 22(3):298-302
  • 3Vassilomanolakis M, Koumakis G, Barbounis V, et al. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines[J]. Ann Oncol, 2000, 11(9):1155-1160
  • 4HohnekerJA. A summary of vinorelbine (navelbine) safety data from north American clinical trials [J]. Semi Oncol, 1994, 21 (5,Suppl 10):42 -47

共引文献26

同被引文献14

  • 1Galano G,Caputo M,Tecce MF,et al.Efficacy and toler- ability of vinorelbine in the cancer therapy[J].Curr Drug Saf,2011,6(3):185-193.
  • 2Ferrero JM,Chamorey E,Magn 6 N,et al.The raltitrexed- vinorelbine combination:a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer[J].Can- cer Chemother Pharmacol,2002,50(6):459-464.doi:10.1007/s00280-002-0519-2.
  • 3Vokes EE,Goh BC,Bertucci D,et al.A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors[J].Cancer,1999,86(3):528-532.
  • 4Judson IR.'Tomudex'(raltitrexed)development:preclinical,phase I and II studies[J].Anticancer Drugs,1997,8(Suppl 2):S5-S9.
  • 5Dong Y,Wang X,Zhang J,et al.Raltitxexed's effect on the development of neural tube defects in mice is associated with DNA damage,apoptosis,and proliferation[J].Mol Cell Biochem,2015,398(1-2):223-231.doi:10.1007/si1010-014-2222-0.
  • 6Wang J,Xu B,Yuan P,et al.Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine main- tenance medication for first-line treatment of patients with advanced breast cancer:Phase 3 randomized trial[J].Cancer,2015,121(19):3412-3421.doi:10.1002/cncr.29492.
  • 7Li M,Fan Y,Li Q,et al.Vinorelbine plus platinum in patients with metastatic triple negative breast cancer and prior anthracycline and taxane treatment[J].Medi- cine(Baltimore),2015,94(43):el928.doi:10.1097/MD.0000000000001928.
  • 8Andreopoulou E,Sparano JA.Chemotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer:an overview[J].Curr Breast Cancer Rep,2013,5(1):42-50.DOI:10.1007/s12609-012-0097-1.
  • 9Xu YC,Wang HX,Tang L,et al.A systematic review of vinorelbine for the treatment of breast cancer[J].Breast J,2013,19(2):180-188.doi:10.1111/tbj.12071.
  • 10Zhang Jian,Wang Leiping,Wang Zhonghua,et al.A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer[J]. Cancer Biology & Therapy,2015,16(2):225-232.doi:10.4161/15384047.2014.986973.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部